A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Inclusion Criteria:

1. Relapsed or refractory follicular lymphoma (FL) (Grade 1, 2 or 3a) or marginal zonelymphoma (MZL) histologically confirmed within 6 months of screening, as assessed bylocal pathology

2. Patients should have received at least one prior therapy that includes anti-CD20 andalkylating agent

3. Follicular lymphoma patients: Received at least one prior line of systemic therapy.Patients that received one prior line of systemic therapy are eligible if theypresent with high risk features. Patients that received two or more prior lines ofsystemic therapy are eligible, assuming one of the prior lines includes anti-CD20and alkylating agent (as listed in criterion 2)

4. Marginal zone lymphoma patients: Received two or more prior lines of systemictherapy, assuming one of the prior lines includes anti-CD20 and alkylating agent (aslisted in criterion 2) or relapsed after hematopoietic stem cell transplant

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

6. Adequate organ function

7. Adequate vascular access for leukapheresis procedure

Exclusion Criteria:

1. Evidence or history of composite Diffuse large B-cell lymphoma (DLBCL) and FL, or oftransformed FL

2. WHO subclassification of duodenal-type FL

3. Central nervous system-only involvement by malignancy (subjects with secondarycentral nervous system (CNS) involvement are allowed on study)

4. History of another primary malignancy that has not been in remission for at least 2years, with the exception of non-invasive malignancies

5. Prior CAR T-cell or other genetically-modified cell therapy

6. History of or active human immunodeficiency virus (HIV)

7. Active hepatitis B or active hepatitis C

8. Uncontrolled systemic fungal, bacterial, viral or other infection despiteappropriate antibiotics or other treatment

9. Active autoimmune disease requiring immunosuppressive therapy

10. Presence of acute or chronic graft-versus-host=disease

11. History of significant cardiovascular disease

12. History or presence of clinically relevant central nervous system pathology

13. Allogenic-hematopoietic stem cell transplant (Allo-HSCT) within 90 days ofleukapheresis